Allergy diagnostics market seen reaching $16.2 billion by 2033

Persistence Market Research projects the global allergy diagnostics market will grow from $7.1 billion in 2026 to $16.2 billion by 2033, driven by rising allergy rates, broader use of in-vitro testing and stronger demand for early diagnosis. North America remains the largest market, while Asia Pacific is emerging as the fastest-growing region.

Why it matters: - Allergy testing is becoming a bigger part of preventive care as allergic diseases spread across age groups and health systems push for earlier diagnosis. - The market growth points to rising demand for more accurate testing, faster workflows and personalized treatment decisions. - Healthcare providers are expanding allergy testing services to help reduce complications and long-term costs.

What happened: - Persistence Market Research estimates the global allergy diagnostics market will be worth US$7.1 billion in 2026 and reach US$16.2 billion by 2033. - The forecast implies a 12.5% compound annual growth rate from 2026 to 2033. - The report highlights rising awareness of allergy-related conditions, greater use of advanced diagnostic technologies and growing demand for early disease detection. - The report points to improved laboratory capabilities, digital healthcare integration and more specialized diagnostic centers as market supports.

The details: - In-vitro diagnostic testing is the leading product segment because of its accuracy, convenience and wider acceptance among clinicians. - Hospitals and diagnostic laboratories are the largest end-user segment because of their testing infrastructure and skilled staff. - North America leads the market due to higher healthcare spending, stronger reimbursement systems, broad awareness and ongoing diagnostic investment. - The market is segmented by product type, allergen type, test type and end user. - Product categories include consumables, instruments and services. - Test types include in-vivo and in-vitro diagnostics, with in-vitro methods gaining wider use because they provide precise results and less patient discomfort. - Allergen categories include inhaled allergens, food allergens, drug allergens and other environmental allergens. - Hospitals, diagnostic laboratories, specialty clinics and research institutes are the main end users. - The report says collaboration between healthcare providers and diagnostic companies is improving testing access in urban and semi-urban areas. - Investments in laboratory automation and digital reporting systems are streamlining workflows and improving patient convenience. - Key companies listed in the market include Thermo Fisher Scientific, Danaher, Siemens Healthineers, bioMérieux, HYCOR Biomedical, Omega Diagnostics Group, Lincoln Diagnostics, Hitachi, Stallergenes Greer and EUROIMMUN Medizinische Labordiagnostika. - The report offers a free sample at More information. - The report also offers customization at Request customization. - The full report is available at Buy the full report.

Between the lines: - The forecast suggests allergy diagnostics is shifting from a niche testing category to a larger routine-care market. - Molecular diagnostics and automation are emerging as key efficiency drivers, which could favor larger labs and established device makers. - Asia Pacific's growth profile suggests the next wave of demand may come from expanding healthcare access rather than mature reimbursement systems.

What's next: - Market growth is likely to track rising allergy prevalence, wider digital health adoption and continued investment in laboratory infrastructure. - Emerging economies may become a bigger source of demand as awareness, access and testing capacity improve. - Companies that offer affordable, accurate and patient-friendly diagnostics may gain an edge through 2033.